Forty Seven Inc. has $75m in Series A venture capital and something else that's pretty novel for a startup biotechnology company: an immuno-oncology development program that's already in the clinic with data expected later this year.
Palo Alto, California-based Forty Seven made a big bet on lead therapeutic candidate Hu5F9-G4 and the cancer treatment's target by...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?